Related Experiment Video
Updated: Aug 5, 2026
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Mutation analysis of the Smad3 gene in human ovarian cancers
1Department of Obstetrics and Gynecology, Gunma University School of Medicine, Maebashi, Gunma, Japan.
Abstract:
The Smad3 gene is a member of the Smad family, vertebrate homologues of Drosophila Mad, and its gene product is a cytoplasmic element in the transforming growth factor-beta (TGF-beta) signaling pathway. Mutations in TGF-beta receptors and their cytoplasmic elements of transduction signals commonly accompany various cancers. Using PCR-SSCP analysis we searched for the presence of Smad3 gene mutations in 36 human ovarian cancers, and found that 15 cases (41. 7%) had a polymorphism at codon 103. Because this mutation was not accompanied by amino acid replacement, the present results show that the mutations in the Smad3 gene are unlikely to be involved in human ovarian cancers.
Insights
Smad3 gene mutations are uncommon in ovarian cancers. A polymorphism at codon 103 was found in 41.7% of cases but did not alter amino acids, suggesting Smad3 is not a major driver of ovarian cancer development.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- The Smad3 gene is crucial in the transforming growth factor-beta (TGF-beta) signaling pathway.
- Alterations in TGF-beta signaling components are frequently observed in various cancers, including ovarian cancer.
Purpose of the Study:
- To investigate the presence and significance of Smad3 gene mutations in human ovarian cancers.
Main Methods:
- Polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) analysis was employed.
- The Smad3 gene was examined in a cohort of 36 human ovarian cancer samples.
Main Results:
- A polymorphism at codon 103 of the Smad3 gene was identified in 15 out of 36 (41.7%) ovarian cancer cases.
- This specific polymorphism did not result in an amino acid substitution, indicating it is a silent mutation.
Conclusions:
- The identified Smad3 gene polymorphism at codon 103 is unlikely to play a significant role in the pathogenesis of human ovarian cancers.
- Further research may be needed to explore other genetic alterations in the TGF-beta pathway in ovarian cancer.
